ArticleNature communications2026
Learning chemical-induced gene expression perturbations with WAVE.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chemical-induced transcriptional profiles facilitate systematic characterization of compound-driven perturbations, offering critical insights into mechanisms of action, especially for compounds with poorly defined molecular targets. However, experimentally profiling gene expression across all combinations of cell lines and compounds is impractical, limiting the large-scale application of comparative transcriptomics in drug screening. To address this, we developed a deep learning framework named WAVE (Wave Action-of-Drug with Variational Encoder), which predicts gene expression profiles from chemical structures and the basal states of cell lines and single cells. By effectively integrating drug molecular representations and cellular basal transcriptional profile using a β-variational autoencoder (β-VAE) framework, WAVE accurately predicts untested chemical-induced transcriptional profiles. Leveraging this integration of cellular insights and molecular characteristics, WAVE excels in drug discovery and drug repurposing based on in silico perturbation experiment. It's application in lung adenocarcinoma (LUAD) drug discovery showcased its potential to identify potentially effective compounds. Our results demonstrate the utility of WAVE for elucidating mechanisms of action for potential drugs and enabling large-scale drug screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.